12/3/2019 9:51 AM
Gene therapy concern Audentes Therapeutics Inc (NASDAQ:BOLD) has more than doubled this morning, surging 104.9% to trade at $58.63, on news that Japan-based drugmaker Astellas Pharma is set to buy th...
10/3/2019 11:32 AM
Drugmaker Audentes Therapeutics Inc (NASDAQ:BOLD) is down 1.4% at $27.32 today, after Baird initiated coverage on the stock with an "underperform" rating. The analyst also slapped BOLD with a $10 pri...